Fluorouracil

Generic Name
Fluorouracil
Brand Names
Actikerall, Carac, Efudex, Fluoroplex, Tolak
Drug Type
Small Molecule
Chemical Formula
C4H3FN2O2
CAS Number
51-21-8
Unique Ingredient Identifier
U3P01618RT
Background

A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication

For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including ...

Associated Conditions
Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
Associated Therapies
-
Clinical Trials
Related News

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

First Posted Date
2022-05-09
Last Posted Date
2024-12-20
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
305
Registration Number
NCT05365581
Locations
🇰🇷

Site KR82003, Seocho-gu, Seoul, Korea, Republic of

🇰🇷

Site KR82005, Seodaemun-gu, Seoul, Korea, Republic of

🇰🇷

Site KR82001, Guro-gu, Seoul, Korea, Republic of

and more 35 locations

Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

First Posted Date
2022-04-15
Last Posted Date
2024-07-23
Lead Sponsor
Gilead Sciences
Target Recruit Count
77
Registration Number
NCT05330429
Locations
🇺🇸

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States

🇺🇸

Virginia Cancer Specialists, PC, Arlington, Virginia, United States

🇺🇸

Seattle Cancer Care Alliance (SCCA), Seattle, Washington, United States

and more 48 locations

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

First Posted Date
2022-04-15
Last Posted Date
2024-12-18
Lead Sponsor
Arcus Biosciences, Inc.
Target Recruit Count
360
Registration Number
NCT05329766
Locations
🇰🇷

Asan Medical Center Hospital, Seoul, Korea, Republic of

🇺🇸

Mayo Clinic - Arizona, Phoenix, Arizona, United States

🇺🇸

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 52 locations

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

First Posted Date
2022-04-08
Last Posted Date
2023-09-18
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
20
Registration Number
NCT05319639
Locations
🇨🇳

Fujian cancer hospital, Fuzhou, Fujian, China

Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

First Posted Date
2022-04-07
Last Posted Date
2024-12-10
Lead Sponsor
John Neoptolemos
Target Recruit Count
394
Registration Number
NCT05314998
Locations
🇩🇪

Universitätsklinikum Augsburg, III. medizinische Klinik, Augsburg, Germany

🇩🇪

DIK Deggendorf, Onkologische Ambulanz, Deggendorf, Germany

🇩🇪

Universitätsklinikum Frankfurt, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie,, Frankfurt, Germany

and more 30 locations

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

First Posted Date
2022-03-25
Last Posted Date
2022-03-25
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
20
Registration Number
NCT05296005
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

First Posted Date
2022-03-18
Last Posted Date
2024-11-26
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
48
Registration Number
NCT05286814
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29

First Posted Date
2022-02-24
Last Posted Date
2024-07-25
Lead Sponsor
Gruppo Oncologico del Nord-Ovest
Target Recruit Count
63
Registration Number
NCT05253846
Locations
🇮🇹

U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - University of Pisa, Pisa, Italy

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

First Posted Date
2022-02-24
Last Posted Date
2024-11-13
Lead Sponsor
Seagen Inc.
Target Recruit Count
400
Registration Number
NCT05253651
Locations
🇺🇸

Palo Verde Cancer Specialists, Glendale, Arizona, United States

🇺🇸

Mayo Clinic Arizona, Phoenix, Arizona, United States

🇺🇸

Pacific Cancer Medical Center, Anaheim, California, United States

and more 229 locations

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

First Posted Date
2022-02-15
Last Posted Date
2024-12-06
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
100
Registration Number
NCT05239741
Locations
🇨🇳

The First Affiliated Hospital of Chongqing Medical University ( Site 0051), Chongqing, Chongqing, China

🇨🇳

Beijing Cancer hospital-Digestive Oncology ( Site 0001), Beijing, Beijing, China

🇨🇳

Beijing Peking Union Medical College Hospital-Medical Oncology ( Site 0011), Beijing, Beijing, China

and more 29 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy